Transcriptional Signatures as a Disease-Specific and Predictive Inflammatory Biomarker for Type 1 Diabetes

The complex milieu of inflammatory mediators associated with many diseases is often too dilute to directly measure in the periphery, necessitating development of more sensitive measurements suitable for mechanistic studies, earlier diagnosis, guiding therapeutic decisions and monitoring interventions. We previously demonstrated that plasma samples from recent-onset type 1 diabetes (RO T1D) patients induce a proinflammatory transcriptional signature in freshly drawn peripheral blood mononuclear cells (PBMCs) relative to that of unrelated healthy controls (HC). Here, using cryopreserved PBMC, we analyzed larger RO T1D and HC cohorts, examined T1D progression in pre-onset samples, and compared the RO T1D signature to those associated with three disorders characterized by airway infection and inflammation. The RO T1D signature, consisting of interleukin-1 cytokine family members, chemokines involved in immunocyte chemotaxis, immune receptors and signaling molecules, was detected during early pre-diabetes and found to resolve post-onset. The signatures associated with cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, patients with confirmed bacterial pneumonia, and subjects with H1N1 influenza all reflected immunological activation, yet each were distinct from one another and negatively correlated with that of T1D. This study highlights the remarkable capacity of cells to serve as biosensors capable of sensitively and comprehensively differentiating immunological states.

[1]  J. Nerup,et al.  Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. , 1986, Science.

[2]  J. Klein,et al.  Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract Infections , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Eizirik,et al.  IL‐1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non‐obese diabetic (NOD) mice , 1997, Clinical and experimental immunology.

[4]  E. Bognetti,et al.  Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty , 1998, Acta Diabetologica.

[5]  E. Bonifacio,et al.  Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[6]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[7]  R. Medzhitov,et al.  Innate immune recognition: mechanisms and pathways , 2000, Immunological reviews.

[8]  W. Hagopian,et al.  A novel high-throughput method for accurate, rapid, and economical measurement of multiple type 1 diabetes autoantibodies. , 2000, Journal of immunological methods.

[9]  M. Trucco,et al.  Protection of Human Islets from the Effects of Interleukin-1β by Adenoviral Gene Transfer of an IκB Repressor* , 2000, The Journal of Biological Chemistry.

[10]  P. Robbins,et al.  Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. , 2000, The Journal of biological chemistry.

[11]  M. Rewers,et al.  Transient antiislet autoantibodies: infrequent occurrence and lack of association with "genetic" risk factors. , 2000, The Journal of clinical endocrinology and metabolism.

[12]  Christophe Benoist,et al.  β-Cell death during progression to diabetes , 2001, Nature.

[13]  M. Atkinson,et al.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment , 2001, The Lancet.

[14]  F. Nicoletti,et al.  Serum levels of the interferon-γ-inducing cytokine interleukin-18 are increased in individuals at high risk of developing Type I diabetes , 2001, Diabetologia.

[15]  Joshua M. Korn,et al.  The plasticity of dendritic cell responses to pathogens and their components. , 2001, Science.

[16]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[17]  Giovanna Lucchini,et al.  The Plasticity of Dendritic Cell Responses to Pathogens and Their Components , 2001 .

[18]  C Benoist,et al.  beta-Cell death during progression to diabetes. , 2001, Nature.

[19]  M. Tarakçıoğlu,et al.  Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. , 2001, Clinical biochemistry.

[20]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[21]  F. Nicoletti,et al.  Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease , 2002, Diabetologia.

[22]  Adrian Ozinsky,et al.  Toll-like receptors: key mediators of microbe detection. , 2002, Current opinion in immunology.

[23]  D. Wilkinson Gene Expression Patterns , 2002, Brain Research.

[24]  M. J. Cody,et al.  TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. , 2002, Nature immunology.

[25]  John Quackenbush,et al.  Genesis: cluster analysis of microarray data , 2002, Bioinform..

[26]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[27]  M. Crow,et al.  Microarray Analysis of Interferon-regulated Genes in SLE , 2003, Autoimmunity.

[28]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[29]  Gerard J. Nau,et al.  Cumulative Toll-Like Receptor Activation in Human Macrophages Treated with Whole Bacteria1 , 2003, The Journal of Immunology.

[30]  W. Klitz,et al.  New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. , 2003, Tissue antigens.

[31]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[32]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Gøtzsche,et al.  Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: A marker of therapeutic success?—A 30‐year Cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection , 2004, Pediatric pulmonology.

[34]  H. Thomas,et al.  IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. , 2004, Diabetes.

[35]  T. Mandrup-Poulsen,et al.  The role of interleukin-1 in the pathogenesis of IDDM , 1996, Diabetologia.

[36]  M. Hussain,et al.  Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM , 1996, Diabetologia.

[37]  B. CeciliaAlbala,et al.  Niveles plasmáticos de citoquinas IL-1ß, IL2 e IL-4 en niños diabéticos tipo 1 de diagnóstico reciente y su asociación con anticuerpos ß pancreáticos , 2004 .

[38]  Marlene Wolf,et al.  Chemokines: multiple levels of leukocyte migration control. , 2004, Trends in immunology.

[39]  J. Santos,et al.  [Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies]. , 2004, Revista medica de Chile.

[40]  Edwin Liu,et al.  Type 1 diabetes: recent developments , 2004, BMJ : British Medical Journal.

[41]  M. Denton,et al.  Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center , 2004, Pediatric pulmonology.

[42]  Steven A Greenberg,et al.  Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. , 2005, Annals of neurology.

[43]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[44]  Richard A. Young,et al.  Insights into host responses against pathogens from transcriptional profiling , 2005, Nature Reviews Microbiology.

[45]  Ziv Bar-Joseph,et al.  STEM: a tool for the analysis of short time series gene expression data , 2006, BMC Bioinformatics.

[46]  C. Tibbetts,et al.  Surveillance of transcriptomes in basic military trainees with normal, febrile respiratory illness, and convalescent phenotypes , 2005, Genes and Immunity.

[47]  P. Gregersen,et al.  Peripheral blood gene expression profiling in rheumatoid arthritis , 2005, Genes and Immunity.

[48]  G. Pinkus,et al.  Interferon‐α/β–mediated innate immune mechanisms in dermatomyositis , 2005 .

[49]  Nathan D. Wolfe,et al.  Common and Divergent Immune Response Signaling Pathways Discovered in Peripheral Blood Mononuclear Cell Gene Expression Patterns in Presymptomatic and Clinically Apparent Malaria , 2006, Infection and Immunity.

[50]  B. Ustundag,et al.  Serum IL-1β, IL-2, and IL-6 in Insulin-Dependent Diabetic Children , 2006, Mediators of inflammation.

[51]  D. Huang,et al.  Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. , 2006, The Journal of infectious diseases.

[52]  M. Daveau,et al.  Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis , 2006, Arthritis research & therapy.

[53]  S. Handley,et al.  Histamine signaling through the H(2) receptor in the Peyer's patch is important for controlling Yersinia enterocolitica infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Cotreau,et al.  Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. , 2006, The Journal of molecular diagnostics : JMD.

[55]  M. Abdul-Rasoul,et al.  ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors , 2006, Pediatric diabetes.

[56]  T. Behrens,et al.  A distinct inflammatory gene expression profile in patients with psoriatic arthritis , 2006, Genes and Immunity.

[57]  J. Pugin,et al.  Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. , 2007, Blood.

[58]  E. Segal,et al.  Zinc‐ion binding and cytokine activity regulation pathways predicts outcome in relapsing–remitting multiple sclerosis , 2007, Clinical and experimental immunology.

[59]  M. Feldmann,et al.  Molecular Profile of Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis , 2007, Molecular medicine.

[60]  Å. Lernmark,et al.  The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design , 2007, Pediatric diabetes.

[61]  J. Farrar,et al.  Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. , 2007, The Journal of infectious diseases.

[62]  W. A. LaFramboise,et al.  Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy , 2007, Journal of the Neurological Sciences.

[63]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[64]  Virginia Pascual,et al.  Gene expression in peripheral blood mononuclear cells from children with diabetes. , 2007, The Journal of clinical endocrinology and metabolism.

[65]  Jing Chen,et al.  Improved human disease candidate gene prioritization using mouse phenotype , 2007, BMC Bioinformatics.

[66]  P. Gregersen,et al.  An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity , 2007, Molecular medicine.

[67]  B. Williams,et al.  Tissue-Specific and Inducer-Specific Differential Induction of ISG56 and ISG54 in Mice , 2007, Journal of Virology.

[68]  Virginia Pascual,et al.  Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade , 2009, The Journal of Experimental Medicine.

[69]  W. LaFramboise,et al.  Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. , 2007, Journal of the neurological sciences.

[70]  A. Achiron,et al.  Impaired Expression of Peripheral Blood Apoptotic‐Related Gene Transcripts in Acute Multiple Sclerosis Relapse , 2007, Annals of the New York Academy of Sciences.

[71]  Dirk Repsilber,et al.  Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis , 2007, Journal of Molecular Medicine.

[72]  J. Banchereau,et al.  Gene expression patterns in blood leukocytes discriminate patients with acute infections. , 2007, Blood.

[73]  C. Wijbrandts,et al.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients , 2007, Annals of the rheumatic diseases.

[74]  J. Skyler Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects , 2007, Clinical pharmacology and therapeutics.

[75]  Huriya Beyan,et al.  Distinct Monocyte Gene-Expression Profiles in Autoimmune Diabetes , 2008, Diabetes.

[76]  M. Hessner,et al.  Identification of a Molecular Signature in Human Type 1 Diabetes Mellitus Using Serum and Functional Genomics1 , 2008, The Journal of Immunology.

[77]  D. Voehringer,et al.  Disease-specific gene expression profiling in multiple models of lung disease. , 2008, American journal of respiratory and critical care medicine.

[78]  T. Mandrup-Poulsen,et al.  The anti‐interleukin‐1 in type 1 diabetes action trial—background and rationale , 2009, Diabetes/metabolism research and reviews.

[79]  Jing Chen,et al.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..

[80]  P. Bingley,et al.  The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results , 2009, Pediatric diabetes.

[81]  M. Peakman,et al.  Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes , 2010, Nature Reviews Immunology.

[82]  M. Hessner,et al.  Identification of a Serum-Induced Transcriptional Signature Associated With Type 1 Diabetes in the BioBreeding Rat , 2010, Diabetes.

[83]  A. Ziegler,et al.  Prediction and pathogenesis in type 1 diabetes. , 2010, Immunity.

[84]  J. Bollyky,et al.  Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes. , 2010, Clinical immunology.

[85]  M. Hessner,et al.  Use of transcriptional signatures induced in lymphoid and myeloid cell lines as an inflammatory biomarker in Type 1 diabetes. , 2011, Physiological genomics.

[86]  Sabine Van Huffel,et al.  Improved performance on high-dimensional survival data by application of Survival-SVM , 2011, Bioinform..

[87]  P. White,et al.  Preliminary studies related to anti‐interleukin‐1β therapy in children with newly diagnosed type 1 diabetes , 2011, Pediatric diabetes.